Subclinical thyroid dysfunction and depressive symptoms:protocol for a systematic review and individual participant data meta-analysis of prospective cohort studies by Wildisen, Lea et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Subclinical thyroid dysfunction and depressive symptoms
Wildisen, Lea; Moutzouri, Elisavet; Beglinger, Shanthi; Syrogiannouli, Lamprini; Cappola,
Anne R.; Åsvold, Bjørn O.; Bakker, Stephan J. L.; Ceresini, Graziano; Dullaart, Robin;
Ferrucci, Luigi; Grabe, Hans; Jukema, J. Wouter; Nauck, Matthias; Trompet, Stella; Voelzke,
Henry; Westendorp, Rudi G. J.; Gussekloo, Jacobijn; Peeters, Robin P.; Kloeppel, Stefan;
Aujesky, Drahomir; Bauer, Douglas C.; Rodondi, Nicolas; Del Giovane, Cinzia; Feller, Martin
Published in:
BMJ Open
DOI:
10.1136/bmjopen-2019-029716
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Wildisen, L., Moutzouri, E., Beglinger, S., Syrogiannouli, L., Cappola, A. R., Åsvold, B. O., ... Feller, M. (2019).
Subclinical thyroid dysfunction and depressive symptoms: protocol for a systematic review and individual
participant data meta-analysis of prospective cohort studies. BMJ Open, 9(7), [029716].
https://doi.org/10.1136/bmjopen-2019-029716
Download date: 03. Feb. 2020
1Wildisen L, et al. BMJ Open 2019;9:e029716. doi:10.1136/bmjopen-2019-029716
Open access 
Subclinical thyroid dysfunction and 
depressive symptoms: protocol for a 
systematic review and individual 
participant data meta-analysis of 
prospective cohort studies
Lea Wildisen,  1 Elisavet Moutzouri,1,2 Shanthi Beglinger,1,2 Lamprini Syrogiannouli,1 
Anne R Cappola,3 Bjørn O Åsvold,4,5 Stephan J L Bakker,6 Graziano Ceresini,7 
Robin Dullaart,6 Luigi Ferrucci,8 Hans Grabe,9 J Wouter Jukema,10 
Matthias Nauck,11,12 Stella Trompet,13 Henry Völzke,9 Rudi G J Westendorp,14 
Jacobijn Gussekloo,13,15 Robin P Peeters,16 Stefan Klöppel,17 Drahomir Aujesky,2 
Douglas C Bauer,18 Nicolas Rodondi,1,2 Cinzia Del Giovane,1 Martin Feller,1,2 for the 
Thyroid Studies Collaboration
To cite: Wildisen L, Moutzouri E, 
Beglinger S, et al.  Subclinical 
thyroid dysfunction and 
depressive symptoms: protocol 
for a systematic review and 
individual participant data 
meta-analysis of prospective 
cohort studies. BMJ Open 
2019;9:e029716. doi:10.1136/
bmjopen-2019-029716
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
029716).
Received 8 February 2019
Revised 3 May 2019
Accepted 14 June 2019
For numbered affiliations see 
end of article.
Correspondence to
Lea Wildisen;  
 lea. wildisen@ biham. unibe. ch
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
Introduction Prospective cohort studies on the 
association between subclinical thyroid dysfunction and 
depressive symptoms have yielded conflicting findings, 
possibly because of differences in age, sex, thyroid-
stimulating hormone cut-off levels or degree of baseline 
depressive symptoms. Analysis of individual participant 
data (IPD) may help clarify this association.
Methods and analysis We will conduct a systematic 
review and IPD meta-analysis of prospective studies on 
the association between subclinical thyroid dysfunction 
and depressive symptoms. We will identify studies through 
a systematic search of the literature in the Ovid Medline, 
Ovid Embase, Cochrane Central Register of Controlled 
Trials (CENTRAL) and Cumulative Index to Nursing and 
Allied Health Literature (CINAHL) databases from inception 
to April 2019 and from the Thyroid Studies Collaboration. 
We will ask corresponding authors of studies that meet 
our inclusion criteria to collaborate by providing IPD. 
Our primary outcome will be depressive symptoms at 
the first available individual follow-up, measured on a 
validated scale. We will convert all the scores to the Beck 
Depression Inventory scale. For each cohort, we will 
estimate the mean difference of depressive symptoms 
between participants with subclinical hypothyroidism 
or hyperthyroidism and control adjusted for depressive 
symptoms at baseline. Furthermore, we will adjust our 
multivariable linear regression analyses for age, sex, 
education and income. We will pool the effect estimates 
of all studies in a random-effects meta-analysis. 
Heterogeneity will be assessed by I2. Our secondary 
outcomes will be depressive symptoms at a specific 
follow-up time, at the last available individual follow-up 
and incidence of depression at the first, last and at a 
specific follow-up time. For the binary outcome of incident 
depression, we will use a logistic regression model.
Ethics and dissemination Formal ethical approval is not 
required as primary data will not be collected. Our findings 
will have considerable implications for patient care. We 
will seek to publish this systematic review and IPD meta-
analysis in a high-impact clinical journal.
PrOsPErO registration number CRD42018091627.
IntrOduCtIOn
Mild degrees of thyroid dysfunction are 
common in the general population, espe-
cially among the older population.1 Patients 
are usually diagnosed with subclinical thyroid 
dysfunction if their serum thyroid-stimulating 
hormone (TSH) levels are either abnormally 
high or low, but their serum free thyroxine (ft4) 
strengths and limitations of this study
 ► This will be the first systematic review and me-
ta-analysis with individual participant data (IPD) to 
assess the association between subclinical thyroid 
dysfunction and depressive symptoms.
 ► By using IPD instead of aggregate data, we can 
define thyroid dysfunction based on the same cri-
teria across all included studies, which will reduce 
between-study heterogeneity, and we can analyse 
subgroups without ecological fallacy.
 ► We will investigate the association between subclin-
ical thyroid dysfunction and depressive symptoms 
in different subgroups (age, sex, prior depressive 
symptoms and different levels of thyroid-stimulating 
hormone).
 ► A possible limitation of this study could be that 
studies used different scales to measure depressive 
symptoms, so we will convert all the scores to the 
Beck Depression Inventory scale to make the scale 
consistent across studies.
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normal.1 A subclinical thyroid dysfunction diagnosis may be 
associated with several negative health outcomes; depression 
is one of them.
Studies that have explored the association between 
subclinical thyroid dysfunction and depressive symptoms 
have yielded conflicting results. Some observational studies 
report that depressive symptoms were more prevalent in 
patients with subclinical hypothyroidism (SHypo) than in 
euthyroid patients.1 2 A cross-sectional study that included 
over 7500 participants found no association between SHypo 
and clinically relevant depression, but did find an association 
between subclinical hyperthyroidism (SHyper) and clinically 
relevant depressive symptoms.3 Another cross-sectional study 
(606 participants) found that neither SHypo nor SHyper 
were associated with depressive symptoms.4 The largest 
prospective study (220 545 participants) reported in the 
literature to date found no association between SHypo and 
incidence of depressive symptoms after 2 years of follow-up.5 
Another prospective study (606 participants) found a signif-
icant association between SHyper and depressive symptoms, 
but not with SHypo.4
These inconsistencies could be due to differences in 
participant’s age, sex or prior depressive symptoms. By 
analysing individual participant data (IPD) from large 
cohort studies, we can define the influence of age, sex and 
prior depressive symptoms. IPD meta-analysis is considered 
to be the best way for synthesising evidence across several 
studies because it is not subject to ecological fallacy.6
Objectives
This systematic review and IPD meta-analysis aims to 
determine the difference in depressive symptoms between 
adult participants with SHypo or SHyper and adults with a 
normal thyroid function (euthyroid participants) during 
follow-up.
MEthOds And AnAlysIs
The protocol adheres to the preferred reporting items for 
systematic reviews and meta-analyses  (PRISMA) statement 
for IPD systematic reviews7 and to the PRISMA statement 
for systematic review protocols (Checklist Table in online 
supplementary 1.1). The protocol was registered with the 
International Prospective Register of Systematic Reviews 
(PROSPERO) on 15 May 2018.
Eligibility criteria
We will include studies in any language and any year of publi-
cation. We will also consider unpublished studies.
Study design
This systematic review will include prospective cohort studies 
that reported data on thyroid function (serum TSH and fT4 
if available) at baseline, and prospective follow-up data on 
depressive symptoms.
We will consider any length of follow-up. Case studies 
or case series (ie, studies exclusively focusing on partici-
pants with thyroid dysfunction) will not be eligible. We will 
exclude studies that only include depressed participants, 
only pregnant or postpartum participants or women who 
were planning to conceive. We will exclude those studies 
because we do not want to have depressed or pregnant 
women over-represented in our study. This does not mean 
that we will exclude single depressed or pregnant individuals 
from studies.
Participants
We will include participants 18 years and older. We will 
exclude participants with overt hypothyroidism or hyperthy-
roidism from the analysis, as most indications are clear for 
treatment of these conditions.
Exposed and control groups
The exposed group will be participants with SHyper or 
SHypo. We define SHyper as TSH level <0.45 mIU/L 
with normal fT4 levels and we define SHypo as TSH 
levels ≥4.5 mIU/L and <20 mIU/L with normal fT4 levels, as 
in our previous analyses.8 9 The range for normal fT4 will 
be defined as study-specific reference ranges similar to our 
previous IPD analyses.6 9 Participants with missing fT4 but 
TSH levels within the range of SHypo or SHyper will also be 
included in the exposed group, because most people with 
TSH levels in this range have subclinical rather than overt 
thyroid dysfunction.10 The control group will be euthyroid 
participants, defined as having TSH levels between 0.45 and 
4.49 mIU/L.
Outcomes
We will consider studies with data on depressive symp-
toms measured on a validated continuous scale (eg, 
Beck Depression Inventory (BDI), Geriatric Depression 
Scale (GDS), etc). For the dichotomous outcome, we will 
consider data on incident depression among others diag-
nosed through International Classification of Diseases, 
10th revision (ICD-10) or Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition (DSM-V) codes or by 
established cut-off levels for incident depression on contin-
uous depression scales.
study outcomes
Our primary outcome will be depressive symptoms measured 
on a continuous scale at the first individual available 
follow-up. The secondary outcomes will be depressive symp-
toms measured on a continuous scale at a specific follow-up 
time point (eg, at year 3 follow-up; decision depending 
on data availability) and at the last available individual 
follow-up. We will convert all the depressive symptoms scales 
to the BDI scale to have a consistent scale across the study 
for better interpretation of the results. The use of follow-up 
data as outcome adjusted for baseline instead of the change 
between follow-up and baseline is recommended for analysis 
of IPD data, especially if baseline data are balanced between 
groups.11 A further secondary outcome will be the incidence 
of depression (binary outcome) at the first follow-up, at a 
specific follow-up (eg, at year 3 follow-up) and at the last 
available individual follow-up.
by copyright.
 o
n
 O
ctober 8, 2019 at Kobenhavns Universitets Bibliotek. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029716 on 26 July 2019. Downloaded from 
3Wildisen L, et al. BMJ Open 2019;9:e029716. doi:10.1136/bmjopen-2019-029716
Open access
Information sources and search strategy
We will include eligible studies from the Thyroid Studies 
Collaboration (TSC) and we will search the Ovid Medline, 
Ovid Embase, Cochrane Central Register of Controlled 
Trials (CENTRAL) and Cumulative Index to Nursing and 
Allied Health Literature  (CINAHL) electronic databases 
from inception through May 2019. We developed the search 
strategy together with two experienced librarians. We devel-
oped the search strategies in Ovid Medline and translated 
it to match the subject headings and keywords for Ovid 
Embase, Cochrane CENTRAL and CINAHL. The following 
items were used: thyroid diseases, hyperthyroidism, hypo-
thyroidism, thyroid hormones, triiodothyronine, thyroxine, 
thyrotropin, subclinical, sub-clinical, mild, subnormal, 
pre-clinical, preclinical and depression. The details of the 
search strategy are provided in online supplementary 1.2. 
No language restriction will be applied.
We will contact members of the TSC ( www. thyroid- studies. 
org), an international network of cohort studies with infor-
mation on thyroid status, and ask to include their unpub-
lished data.
study selection
We will collect all potential articles identified through the 
literature search. Multiple publications from the same 
cohort study will be counted as one study. We will export all 
the identified studies to Endnote X8 and delete duplicates. 
First, two reviewers (LW and EM) will screen the titles and 
abstracts and retain articles that meet our eligibility criteria 
by using a Distiller Systematic Review Software. Second, two 
reviewers (LW and EM) will determine each remaining arti-
cle’s eligibility by reviewing the full text; the reviewers will 
keep a detailed record of reasons for excluding studies. We 
will resolve discrepancies by consensus with a third author 
(MF).
strategy to ask and collect individual participant data
We will use the following strategy to obtain the IPD from 
each cohort. We will contact the corresponding author of 
each study by email and ask them to participate in our study 
by providing IPD. If they do not respond, we will email two 
reminders, including the last and corresponding author. If 
we still do not get any answer, we will consider the collabo-
ration as declined. If a study does not provide IPD, we will 
extract aggregate data from the published study and analyse 
it along with IPD.
We will distribute a list of all the variables that we want to 
include in our analysis to the responsible person from each 
cohort that agreed to participate. The detailed list with all 
the required variables is provided in online supplementary 
1.3. The collaborators will use the list of variables to prepare 
their datasets and send them to us, or we will download the 
data from their online database. We will collect these data-
sets and merge the data into a uniform format (STATA).
study quality
We will assess the quality of included studies on the Newcas-
tle-Ottawa Scale for cohort studies,12 which allocates a 
maximum of nine stars to studies of the highest quality 
based on three parameters: selection of study groups, 
comparability of groups and ascertainment of the outcome 
of interest. Studies will be ranked either high quality (7–9 
stars), moderate quality (4–6 stars) or low quality (0–3 stars).
data analyses
We will conduct an IPD meta-analysis in two-stages. In the 
first stage, we will estimate the association between depres-
sive symptoms and participants with SHypo or SHyper and 
those with normal thyroid function in each cohort with 
multivariable regression analyses (linear regression for 
continuous outcomes and logistic regression for dichoto-
mous outcomes), and adjust for depressive symptoms at 
baseline, age, sex, education and income. For continuous 
outcomes, we will use the mean difference (MD) and its rela-
tive 95% CI. For dichotomous outcomes, we will estimate the 
OR and its relative 95% CI.
For the continuous outcome, we will transfer all the 
measurements from different scales to the BDI scale by calcu-
lating a conversion factor. We will calculate the conversion 
factor by dividing the range of the BDI scale by the range of 
the scale we would like to convert. For example, to convert 
the Center for Epidemiological Studies Depression (CESD) 
scale to the BDI, we would use a conversion factor of 1.05 (63 
(BDI range) ÷ 60 (CESD range)). To transfer the measure-
ments from the CESD scale to the BDI, we will  multiply  each 
individuals CESD value by the conversion factor.
For the dichotomous outcome, we will use established 
cut-off values of the original continuous scales to define 
depression or non-depression or we use diagnosis of depres-
sion through ICD-10 or DSM-V codes among others. For 
example, the CESD score has the best specificity and sensi-
tivity to define incidence ressive symptoms for a cut-off 
value >20.13 In the second stage, we will pool the effect 
measures for each study from the first step using a random 
effects model.
We will assess the heterogeneity by estimating the τ2 
statistic, the I2 and the Q-test and explore the source of 
heterogeneity in several subgroups and sensitivity analyses. 
If we observe a high heterogeneity across study results, we 
will do a meta-regression including the length of follow-up 
for each study.
We will perform subgroup analyses by sex, age (≤57 
years, >75 years), TSH levels (level 1: TSH <0.1 mIU/L, 
level 2: TSH 0.1–0.44 mIU/L, level 3: TSH 4.6–6.9 mIU/L, 
level 4: 7–9.9 mIU/L, level 5: TSH ≥10 mIU/L), ethnicity 
(if enough power), prior depressive episodes (yes/no) and 
thyroxine use at baseline (yes/no).
For the primary outcome, we will conduct several sensi-
tivity analyses:1 exclude participants with prior depressive 
episodes,2 include studies without depressive symptoms' 
data at baseline,3 exclude participants taking antidepres-
sant medications at baseline or during follow-up,4 exclude 
participants with dementia,5 exclude participants who use 
thyroxine or anti-thyroid drugs at baseline and follow-up,6 
exclude participants who use thyroid-altering medication 
(anti-thyroid drugs, thyroxine, amiodarone, lithium),7 
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exclude participants without fT4 measured at baseline,8 
exclude studies that only provide aggregate data. As further 
sensitivity analysis,9 we will calculate MDs using the original 
scale for each study in the first stage and pool the derived 
standardised MDs in the second stage.
We will assess the presence of publication bias and small 
study effects with funnel plots and the Egger test.14 We will 
use STATA V.15 for all analyses. We will use the Grading of 
Recommendations, Assessment, Development and Evalua-
tion (GRADE) approach ( www. gradeworkinggroup. org) to 
assess the confidence on estimates.
Patient and public involvement
Patients were not involved in the development of the 
research question, outcome measure and study design.
EthICs And dIssEMInAtIOn
Formal ethical approval is not required as primary data will 
not be collected. This study may have considerable impli-
cations for practice and help improve patient care. This 
systematic review and IPD meta-analysis will be submitted to 
a high-impact clinical journal.
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